Navigation Links
BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
Date:1/8/2014

s approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium is partnered with Actelion Pharmaceuticals Ltd. for the marketing of XIAFLEX in Canada and Australia, and Swedish Orphan Biovitrium AB for the marketing of XIAPEX® (the EU tradename for CCH) in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome in a Phase 2b study and also for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas. For more information, please visit www.biospecifics.com.

Forward-Looking Statements
This release includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements." The forward-looking statements include statements concerning, among other things, the design and timing of future studies to access the efficacy and safety of CCH for the treatment of human lipoma or their likelihood of success; the potential of CCH for the treatment of human lipomas by comparison with surgery; whether Auxilium will exercise its opt-in rights for human lipoma following the completion of a new trial; and the development of CCH for other
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... CHAPEL HILL, N.C. , June 11 ... groups is a critical part of educating patients and ... consumers as they seek out information on new therapies, ... deep-dive interviews with selected participants, Best Practices, LLC conducted ...
... HILL, N.C. , June 11 The bio-pharma mega-mergers that ... Merck + Schering-Plough - are now in the critical post-integration period and ... their integration plans. , , ... It is too early for final verdicts, but clearly one M&A issue ...
Cached Medicine Technology:Collaborating with Patient Advocacy Groups to Educate Physicians, Patients and Thought Leaders 2Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger 2Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger 3
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
(Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
(Date:7/8/2014)... enjoy similar longevity and cardiovascular health as other healthy ... the American Journal of Transplantation . The findings ... and the transplant professionals caring for them. , Over ... aged 55 years and older has become more common. ... heart disease, the removal of a kidney could make ...
Breaking Medicine News(10 mins):Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2
... black young adults are hospitalized for stroke at a ... peers, a new study by University of South Florida ... the American Heart Association,s Council on Epidemiology and Prevention ... the international journal Neuroepidemiology . , Disparities ...
... the only Minnesota hospitals to receive designation ROCHESTER, Minn., ... Surgical Quality Improvement Program (ACS NSQIP) has recognized Mayo ... of the 26 ACS NSQIP participating hospitals in the ... patient care. As a participant in ACS NSQIP, Mayo ...
... NEW YORK, March 13 Ruth W. Messinger, ... issued a statement today calling on the international ... international aid organizations into Darfur so workers can ... refugees and internally displaced persons throughout Darfur and ...
... Rice University report released yesterday, exactly six months after ... people did not practice the lessons learned from Hurricane ... Harris County residents say they would evacuate if a ... potential increase over the 24 percent of residents who ...
... print news decline and consumer shift to web news -LITTLE FALLS, ... New York Times reports on the closing ... 24/7 Wall St. issued its list of 10 major daily ... only publish online. While the New York Times ...
... with language disorders may benefit from tonal training , , ... the ability to recognize emotion in speech and other ... benefit people with language problems and impaired emotional perception. ... is a skill that translates across all arenas, whether ...
Cached Medicine News:Health News:Black young adults hospitalized for stroke at much higher rate than whites, Hispanics 2Health News:Black young adults hospitalized for stroke at much higher rate than whites, Hispanics 3Health News:American College of Surgeons Recognizes Mayo Hospitals for Exemplary Outcomes 2Health News:American College of Surgeons Recognizes Mayo Hospitals for Exemplary Outcomes 3Health News:Rice report shows lessons from Hurricane Rita not practiced during Ike 2Health News:Print Media Under Siege - Are Readers Disappearing? 2Health News:Musicians' Brains Tuned to Emotions in Sound 2
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
... not leave your hands dry, cracked or ... Antimicrobial action, CHG Skin Cleanser attacks a ... gram-positive bacteria, fungi, and yeasts. It is ... wash. The solution does not contain red ...
BD Persist Plus protective barrier skin preps with chlorhexidine in alcohol...
Medicine Products: